Sun Pharma Launches Anti-Baldness Drug Leqselvi in U.S.

India’s leading pharmaceutical company by revenue, Sun Pharma, has announced the U.S. launch of its anti-baldness drug Leqselvi (8 mg tablets) for the treatment of severe alopecia areata, following the resolution of a patent dispute with Incyte Corp.

The launch had been delayed due to a patent infringement case in a U.S. court, but with the legal issue now settled, Leqselvi will be available to patients across the country.

According to Shrikant Akolkar, analyst at Nuvama Institutional Equities, Leqselvi could achieve up to $400 million in sales by FY30, with peak potential estimated at $900 million, providing a significant growth driver for Sun Pharma’s U.S. business.

“This is a very positive development, as the legal uncertainty is now resolved. The drug has shown strong clinical outcomes, and this launch marks a meaningful expansion of Sun Pharma’s commercial portfolio,” Akolkar noted.

Sun Pharma emphasized that Leqselvi’s addition to its dermatology segment is a strategic milestone as the company continues to diversify into new therapeutic areas.

Alopecia areata is an autoimmune condition that leads to patchy hair loss on the scalp and other parts of the body.

The launch comes amid ongoing pricing pressure and intense competition for Indian drugmakers in the U.S. market, making successful entries into innovative treatment areas all the more crucial.